Silexion Therapeutics 株価情報 (NASDAQ: SLXN)

最新ニュース Silexion Therapeutics (NASDAQ:SLXN) 株価情報

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

<a href="https://www.nintendo.com/us/whatsnew/nintendo-maintains-nintendo-switch-2-pricing-retail-pre-orders-to-begin-april-24-in-u-s/">https://www.nintendo.com/us/whatsnew/nintendo-maintains-nintendo-switch-2-pricing-retail-pre-orders-to-begin-april-24-in-u-s/</a>

News

General

NTDOF

NTDOY

'Nintendo Maintains Nintendo Switch 2 Pricing, Retail Pre-Orders to Begin April 24 in U.S'- Nintendo

The US stock market rebounded sharply as investors cheered President Donald Trump's April 9 announcement to put a 90-day pause on tariffs against all countries except China. While many Wall Street experts view this as a positive development, some believe we're still not out of the woods.
‘Classic' Bear Market
Josh Brown, CNBC commentator and CEO of Ritholtz Wealth Management, said during a recent <a href="https://www.youtube.com/watch?v=kjgmc7gq8MI">segment</a> that he doesn't see the rebound as a healthy pullback and pointed to some "classic" bear market signs. The analyst called the rebound a "bear market bounce." Brown talked about past market rebounds during recessionary periods to prove his point:
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
"I saw all the tables, all the graphs, all the charts. What didn't necessarily accompany that commentary was the context in which we've seen the other nine best days of all time," Brown said. "And I'll spoil it for you—typically, they take place in years like 1933, 2008, and 1931, and they happen when the market is in a 75% drawdown. A 48% drop on October 13th of 2008 was the sixth best day ever. We had a huge 11.6% run, but we were already down 35.9% from the high."
While Brown acknowledged that we are not in a "statistical" bear market, he believes that important sectors with large market caps were in their "own" bear market, and warned affluent investors about the challenges ahead.
"While it was exhilarating and remarkable and a lot of fun, with a lot of backslapping and a lot of rich kids who are really proud of themselves—because they grew up insulated from the consequences of their own actions—the end result today is, ‘Oh wait a minute, maybe we put the financial crisis on hold, but we still get to have a recession,'" he said on CNBC.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The analyst said that he is not shorting the market and avoids being "too negative" but wants to present an accurate picture of the market.
Treasury Market Swings ‘Maniacal'
During the CNBC segment, Brown called the recent volatility in the Treasury market "maniacal" and said that if the Federal Reserve steps in to stabilize the bond market, it would be a negative sign. Browns specifically mentioned the 45 basis-point swing in the 10-year U.S. Treasury yield between April 4 and April 9, which was the biggest since 2022.
"We&#8217;ve only seen that seven other times going back to the year 2000 and on every single instance the S&amp;P was down 25% or worse that we&#8217;ve seen so again that is a classic feature of when the S&amp;P is down big you get those huge swings in the 10-year," Brown said.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Buying Opportunity for Long-Term Investors
Despite the volatility, Brown recommended investors buy only if they have a long-term horizon.
&#8220;You should not expect that the buys you make today will necessarily be rewarded a week from now it&#8217;s just a different environment," said Brown.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Analyst Predicts Recession is Coming Despite Financial Crisis Put on 'Hold' — Warns 'Rich Kids Insulated From Their Own Actions'

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 5 years by 14.36% on an annualized basis producing an average annual return of 28.39%. Currently, Live Nation Entertainment has a market capitalization of $29.40 billion. 
Buying $1000 In LYV: If an investor had bought $1000 of LYV stock 5 years ago, it would be worth $3,470.27 today based on a price of $127.22 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744986614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

First American Division, First American Data & Analytics, Launches VeriTitle To Accelerate The Mortgage And Home Equity Loan Origination Process By Delivering Critical Title Intelligence To Lenders As Borrowers Begin Their Loan Applications

In the latest cryptocurrency market update, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) are all demonstrating potential signs of a bullish reversal, indicating a possible recovery from recent bearish trends.
What Happened: According to data, Bitcoin is testing a key technical formation that could reverse&nbsp;its recent bearish trends. The&nbsp;digital currency is trading just below $85,000, nearing the 200 EMA at approximately $87,500,&nbsp;and challenging the 100 EMA.&nbsp;
A firm&nbsp;close above the 200 EMA&nbsp;could signal&nbsp;a significant death cross reversal, sparking renewed optimism in the broader cryptocurrency market.
In addition to Bitcoin, Solana is also displaying potential signs of a trend reversal. The asset&#8217;s strengthening price performance&nbsp;and a technical setup that&nbsp;has historically signaled the start of bull markets are noteworthy. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44065728/crypto-analyst-predicts-195-bitcoin-rally-says-bull-market-not-over-yet">Crypto Analyst Predicts 195% Bitcoin Rally, Says Bull Market Not Over Yet</a>
Solana has crossed&nbsp;its 50-day Exponential Moving Average&nbsp;(EMA), a critical resistance level often marking the beginning of sustained rallies. Solana&#8217;s current price stands at $134, reflecting a daily increase of over 2%.
Pepe, a popular meme token, is also showing signs of a possible bullish reversal, mirroring Solana&#8217;s trend. A&nbsp;breakout above the 50-day Exponential&nbsp;Moving Average (EMA) has typically signaled trend reversals, and Pepe appears to be following suit. Pepe&#8217;s current price is $0.000000730, marking a daily increase of nearly 2.4%.
Why It Matters: The potential bullish reversals of Bitcoin, Solana, and Pepe are significant indicators of the cryptocurrency market&#8217;s resilience. Despite recent bearish trends, these digital assets are demonstrating their ability to bounce back, which could inspire renewed investor confidence. 
The technical indicators suggest that the market could be entering a period of recovery, which would be a welcome development for investors who have weathered recent market volatility.
Read Next
<a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43901226/robert-kiyosaki-says-everything-bubble-will-cause-historic-market-crash-bitcoin-will-be-fastest-to-recover" target="_blank" rel="noreferrer noopener">Robert Kiyosaki Says ‘Everything Bubble' Will Cause Historic Market Crash, Bitcoin Will Be Fastest To Recover</a>
Image: Shutterstock/alfernec

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

$PEPE

$SOL

Bitcoin, Solana and Pepe Show Bullish Reversal Signs Amid Market Recovery

If you&#8217;re looking to support an adult child with <a href="https://www.benzinga.com/personal-finance/25/04/44778031/she-was-29-months-from-erasing-247k-in-student-debt-now-her-forgiveness-is-frozen">student loan debt</a>, you may be wondering whether there's a tax benefit for doing so — especially if you're in a strong financial position. That's exactly what one listener asked Suze Orman on her "<a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-revisiting-can-i-give-my-child-money-and-get-a-tax-deduction">Women &amp; Money</a>" podcast.
Here's how the question — and Orman's answer — break down.
<h2 class="wp-block-heading">The Gift Tax Exclusion Doesn't Equal a Deduction</h2>
Marlene, a 75-year-old listener, wrote in to ask whether she could give her 50-year-old son $17,000 to help with student loans and get a tax deduction in the process. According to Orman, the answer is no.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
"You can absolutely gift your son or anybody you want&#8230; as many people a year as you want, currently, $18,000 a year," Orman explained. "However, it&#8217;s not taxable to them, and it&#8217;s not a tax write-off to you on any level."
This refers to the <a href="https://www.benzinga.com/money/gift-tax-rate">IRS annual gift tax exclusion</a>, which allowed you to give up to $18,000 per person in 2024, now $19,000 in 2025, without needing to file a gift tax return. But while the gift itself may be tax-free for both giver and receiver, it doesn't reduce your taxable income like a charitable donation or deductible expense might.
<h2 class="wp-block-heading">Helping With Loans Is Generous — But Not Tax-Advantaged</h2>
Even if the funds go directly toward student loans, the IRS still considers that a personal gift. That means it won't trigger a deduction, no matter how good your intentions.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
So what's the alternative? Some people consider donating to a 501(c)(3) nonprofit that provides student loan relief, but that typically won't help your own child. Direct payments to a lender don't qualify as <a href="https://www.benzinga.com/personal-finance/25/02/44044478/kevin-oleary-questions-charity-transparency-his-biggest-concern-with-giving-is-not-knowing-if-the-money-actually-went-where-it-was-promised">charitable giving</a>.
Orman also cautioned listeners not to mix financial goals.&nbsp;
<h2 class="wp-block-heading">Should You Pay the Loan Anyway?</h2>
Although there's no tax break for helping with student loans, Orman encouraged Marlene to think beyond taxes.
"If you&#8217;re very comfortable, does it make you uncomfortable when you see your son suffering under a lot of student loans at the age of 50?" Orman asked. She pointed out that financial help can be meaningful, but only if it's used wisely and doesn't enable poor financial habits.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Ultimately, she advised Marlene to consider whether paying off the loan would actually help her son — or simply enable ongoing financial issues. "You and you alone have to decide that," Orman said.
<h2 class="wp-block-heading">Bottom Line</h2>
You can gift up to $19,000 a year to your child without triggering gift taxes, but it won't give you a tax deduction. If you're in a strong financial position, helping your child with student loans could be a meaningful gesture — but, according to <a href="https://www.benzinga.com/personal-finance/25/04/44715539/suze-orman-says-when-sentiment-is-this-fearful-its-not-the-time-to-sell-but-if-youll-need-the-mo">Orman</a>, it's important to consider whether it truly helps them in the long run.
"I hope that Marlene has the courage to stand in her own truth, no matter which one of those things it happens to be, because she&#8217;s OK no matter what," Orman said.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

'Can I Gift My Son $17,000 For Student Loans And Get A Tax Deduction?' Here's What Suze Orman Says

CTSH

DOCU

Cognizant Technology Solutions Strengthens DocuSign Partnership To Boost Customer Support And Accelerate Digital Transformation

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 2.54% on an annualized basis producing an average annual return of 16.57%. Currently, AbbVie has a market capitalization of $308.15 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $205.96 today based on a price of $174.20 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744985713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) is set to give its latest quarterly earnings report on Monday, 2025-04-21. Here's what investors need to know before the announcement.
Analysts estimate that Calix will report an earnings per share (EPS) of $0.13. 
Investors in Calix are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 8.98% increase in the share price the next day.
Here's a look at Calix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.07</td>
<td>0.09</td>
<td>0.06</td>
<td>0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.13</td>
<td>0.09</td>
<td>0.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>-6.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984912_0.png" alt="eps graph" />
<h3>Performance of Calix Shares</h3>
Shares of Calix were trading at $33.79 as of April 16. Over the last 52-week period, shares are up 14.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Calix</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Calix.
Analysts have provided Calix with 4 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $44.25, suggesting a potential 30.96% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Viavi Solutions, Extreme Networks and NetScout Systems, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Viavi Solutions, with an average 1-year price target of $12.61, suggesting a potential 62.68% downside.</li>
<li>Analysts currently favor an Buy trajectory for Extreme Networks, with an average 1-year price target of $20.0, suggesting a potential 40.81% downside.</li>
<li>Analysts currently favor an Neutral trajectory for NetScout Systems, with an average 1-year price target of $25.0, suggesting a potential 26.01% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for Viavi Solutions, Extreme Networks and NetScout Systems, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calix</td>
<td>Buy</td>
<td>-22.14%</td>
<td>$113.37M</td>
<td>-2.30%</td>
</tr>
<tr>
<td>Viavi Solutions</td>
<td>Buy</td>
<td>6.40%</td>
<td>$160.80M</td>
<td>1.31%</td>
</tr>
<tr>
<td>Extreme Networks</td>
<td>Buy</td>
<td>-5.74%</td>
<td>$175.12M</td>
<td>17.59%</td>
</tr>
<tr>
<td>NetScout Systems</td>
<td>Neutral</td>
<td>15.57%</td>
<td>$205.41M</td>
<td>3.28%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Calix ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Return on Equity.
<h3>Discovering Calix: A Closer Look</h3>
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East &amp; Africa, Europe, Asia Pacific and other markets.
<h3>Understanding the Numbers: Calix's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Calix's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -22.14% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Calix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -8.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.3%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Calix's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.91%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<a href="https://www.benzinga.com/quote/CALX/earnings">To track all earnings releases for Calix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CALX

Preview: Calix's Earnings

Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) is set to give its latest quarterly earnings report on Monday, 2025-04-21. Here's what investors need to know before the announcement.
Analysts estimate that Cadence Bank will report an earnings per share (EPS) of $0.64. 
Cadence Bank bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 4.68% drop in the share price on the following day.
Here's a look at Cadence Bank's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.68</td>
<td>0.64</td>
<td>0.61</td>
<td>0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.73</td>
<td>0.69</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>5.0%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984904_0.png" alt="eps graph" />
<h3>Cadence Bank Share Price Analysis</h3>
Shares of Cadence Bank were trading at $27.89 as of April 16. Over the last 52-week period, shares are up 0.61%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CADE/earnings">To track all earnings releases for Cadence Bank visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CADE

What to Expect from Cadence Bank's Earnings

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-21. Here's a quick overview of what investors should know before the release.
Analysts are estimating that BOK Financial will report an earnings per share (EPS) of $1.99.
BOK Financial bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 0.0% drop in the share price the next day.
Here's a look at BOK Financial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.99</td>
<td>1.98</td>
<td>2.34</td>
<td>1.73</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.12</td>
<td>2.18</td>
<td>2.02</td>
<td>1.91</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984896_0.png" alt="eps graph" />
<h3>Market Performance of BOK Financial's Stock</h3>
Shares of BOK Financial were trading at $90.81 as of April 16. Over the last 52-week period, shares are up 2.14%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BOKF/earnings">To track all earnings releases for BOK Financial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BOKF

Earnings Preview: BOK Financial

Servisfirst Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NYSE">SFBS</a>) is preparing to release its quarterly earnings on Monday, 2025-04-21. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Servisfirst Bancshares to report an earnings per share (EPS) of $1.18.
Investors in Servisfirst Bancshares are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.08, leading to a 2.67% increase in the share price the following trading session.
Here's a look at Servisfirst Bancshares's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.11</td>
<td>0.97</td>
<td>0.91</td>
<td>0.88</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.19</td>
<td>1.10</td>
<td>0.95</td>
<td>0.94</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>2.0%</td>
<td>13.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984887_0.png" alt="eps graph" />
<h3>Tracking Servisfirst Bancshares's Stock Performance</h3>
Shares of Servisfirst Bancshares were trading at $69.32 as of April 16. Over the last 52-week period, shares are up 13.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SFBS/earnings">To track all earnings releases for Servisfirst Bancshares visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SFBS

What's Next: Servisfirst Bancshares's Earnings Preview

Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-21. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Bank of Hawaii will report an earnings per share (EPS) of $0.89.
Investors in Bank of Hawaii are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.78% increase in the share price on the subsequent day.
Here's a look at Bank of Hawaii's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.83</td>
<td>0.82</td>
<td>0.86</td>
<td>0.85</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.85</td>
<td>0.93</td>
<td>0.86</td>
<td>0.87</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984878_0.png" alt="eps graph" />
<h3>Bank of Hawaii Share Price Analysis</h3>
Shares of Bank of Hawaii were trading at $64.23 as of April 17. Over the last 52-week period, shares are up 11.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BOH/earnings">To track all earnings releases for Bank of Hawaii visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Bank of Hawaii's Earnings

Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-21. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Hexcel will report an earnings per share (EPS) of $0.43.
The market awaits Hexcel's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 3.24% increase in the share price on the following day.
Here's a look at Hexcel's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.52</td>
<td>0.46</td>
<td>0.56</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.47</td>
<td>0.60</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984869_0.png" alt="eps graph" />
<h3>Market Performance of Hexcel's Stock</h3>
Shares of Hexcel were trading at $52.11 as of April 16. Over the last 52-week period, shares are down 16.67%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Hexcel</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Hexcel.
A total of 9 analyst ratings have been received for Hexcel, with the consensus rating being Buy. The average one-year price target stands at $71.44, suggesting a potential 37.09% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of AeroVironment and Karman Holdings, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for AeroVironment, with an average 1-year price target of $168.0, suggesting a potential 222.39% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Karman Holdings, with an average 1-year price target of $38.6, suggesting a potential 25.93% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for AeroVironment and Karman Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexcel</td>
<td>Buy</td>
<td>3.56%</td>
<td>$118.50M</td>
<td>0.37%</td>
</tr>
<tr>
<td>AeroVironment</td>
<td>Buy</td>
<td>-10.15%</td>
<td>$63.20M</td>
<td>-0.20%</td>
</tr>
<tr>
<td>Karman Holdings</td>
<td>Outperform</td>
<td>18.50%</td>
<td>$34.73M</td>
<td>0.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Hexcel is positioned at the top for Revenue Growth among its peers. In terms of Gross Profit, Hexcel is also leading the group. However, Hexcel's Return on Equity is below the average of its peers.
<h3>Delving into Hexcel's Background</h3>
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and their respective subcontractors.
<h3>Unraveling the Financial Story of Hexcel</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Hexcel's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Hexcel's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.37%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Hexcel's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Hexcel's debt-to-equity ratio is below the industry average at 0.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/HXL/earnings">To track all earnings releases for Hexcel visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Hexcel's Earnings

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) is set to give its latest quarterly earnings report on Monday, 2025-04-21. Here's what investors need to know before the announcement.
Analysts estimate that Zions Bancorp will report an earnings per share (EPS) of $1.18. 
The market awaits Zions Bancorp's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 1.59% drop in the share price on the subsequent day.
Here's a look at Zions Bancorp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.26</td>
<td>1.17</td>
<td>1.10</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.34</td>
<td>1.37</td>
<td>1.28</td>
<td>1.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>6.0%</td>
<td>6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984860_0.png" alt="eps graph" />
<h3>Performance of Zions Bancorp Shares</h3>
Shares of Zions Bancorp were trading at $43.36 as of April 16. Over the last 52-week period, shares are up 7.16%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ZION/earnings">To track all earnings releases for Zions Bancorp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZION

What to Expect from Zions Bancorp's Earnings

Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) is preparing to release its quarterly earnings on Monday, 2025-04-21. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Wintrust Finl to report an earnings per share (EPS) of $2.49.
Wintrust Finl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.16 in the last quarter, leading to a 2.65% drop in the share price on the following day.
Here's a look at Wintrust Finl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.47</td>
<td>2.51</td>
<td>2.42</td>
<td>2.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.63</td>
<td>2.47</td>
<td>2.32</td>
<td>2.89</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984852_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Wintrust Finl were trading at $101.61 as of April 16. Over the last 52-week period, shares are up 3.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WTFC/earnings">To track all earnings releases for Wintrust Finl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WTFC

Earnings Preview For Wintrust Finl

Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is preparing to release its quarterly earnings on Monday, 2025-04-21. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Medpace Hldgs to report an earnings per share (EPS) of $3.09.
Anticipation surrounds Medpace Hldgs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.55, leading to a 7.52% drop in the share price the following trading session.
Here's a look at Medpace Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.12</td>
<td>2.78</td>
<td>2.54</td>
<td>2.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.67</td>
<td>3.01</td>
<td>2.75</td>
<td>3.20</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-7.000000000000001%</td>
<td>-18.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984844_0.png" alt="eps graph" />
<h3>Medpace Hldgs Share Price Analysis</h3>
Shares of Medpace Hldgs were trading at $296.5 as of April 16. Over the last 52-week period, shares are down 21.26%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Insights on Medpace Hldgs</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Medpace Hldgs.
The consensus rating for Medpace Hldgs is Neutral, derived from 5 analyst ratings. An average one-year price target of $341.6 implies a potential 15.21% upside.
<h3>Peer Ratings Comparison</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Bio-Techne, Avantor and Repligen, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Bio-Techne, with an average 1-year price target of $78.83, suggesting a potential 73.41% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Avantor, with an average 1-year price target of $24.0, suggesting a potential 91.91% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Repligen, with an average 1-year price target of $177.14, suggesting a potential 40.26% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Bio-Techne, Avantor and Repligen, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>7.66%</td>
<td>$178.32M</td>
<td>13.71%</td>
</tr>
<tr>
<td>Bio-Techne</td>
<td>Neutral</td>
<td>8.96%</td>
<td>$193.89M</td>
<td>1.65%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.10%</td>
<td>$562.90M</td>
<td>8.70%</td>
</tr>
<tr>
<td>Repligen</td>
<td>Neutral</td>
<td>0.56%</td>
<td>$38.84M</td>
<td>-1.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Medpace Hldgs ranks highest in gross profit and return on equity among its peers. It is in the middle for revenue growth. The company's consensus rating is neutral.
<h3>Get to Know Medpace Hldgs Better</h3>
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
<h3>Financial Insights: Medpace Hldgs</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Medpace Hldgs displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.66%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Medpace Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 13.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.59%, the company showcases effective utilization of assets.
Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MEDP/earnings">To track all earnings releases for Medpace Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEDP

Insights into Medpace Hldgs's Upcoming Earnings

Mondelez International's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NYSE">MDLZ</a>) short percent of float has risen 16.67% since its last report. The company recently reported that it has 32.61 million shares sold short, which is 2.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mondelez International Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744984838_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mondelez International has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mondelez International's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mondelez International's peer group average for short interest as a percentage of float is 6.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MDLZ

Peering Into Mondelez International's Recent Short Interest

Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) will release its quarterly earnings report on Monday, 2025-04-21. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Western Alliance to report an earnings per share (EPS) of $1.78.
Anticipation surrounds Western Alliance's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.03, leading to a 5.14% drop in the share price the following trading session.
Here's a look at Western Alliance's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.92</td>
<td>1.89</td>
<td>1.70</td>
<td>1.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.95</td>
<td>1.80</td>
<td>1.75</td>
<td>1.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744984833_0.png" alt="eps graph" />
<h3>Western Alliance Share Price Analysis</h3>
Shares of Western Alliance were trading at $65.24 as of April 16. Over the last 52-week period, shares are up 13.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WAL/earnings">To track all earnings releases for Western Alliance visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Western Alliance's Upcoming Earnings Report

Baxter Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) short percent of float has risen 13.65% since its last report. The company recently reported that it has 18.16 million shares sold short, which is 5.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Baxter Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744984833_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Baxter Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Baxter Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Baxter Intl's peer group average for short interest as a percentage of float is 4.30%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Baxter Intl?

Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry

Press Releases

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Health Care

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Comments

Silexion Therapeutics

ニュース

最新ニュース Silexion Therapeutics (NASDAQ:SLXN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル